{
    "clinical_study": {
        "@rank": "119493", 
        "arm_group": [
            {
                "arm_group_label": "Weight Loss + Omega-3 FA", 
                "arm_group_type": "Experimental", 
                "description": "Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)"
            }, 
            {
                "arm_group_label": "Weight Loss + Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if high dose omega-3 fatty acids when added to a\n      weight loss program are well tolerated in the study population and if they increase the\n      favorable change in blood and tissue breast cancer risk factors in the associated with\n      weight loss alone."
        }, 
        "brief_title": "Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Weight Loss"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Evidence of Hyperplasia with Masood score of 13 or higher and 500 or more epithelial\n             cells on cytology slide of screening Random Periareolar Fine Needle Aspiration\n             (RPFNA)\n\n          -  Access to smart phone and or computer\n\n          -  Willing to comply with diet, exercise and lifestyle modification during weight\n             reduction and maintenance phase.\n\n          -  Willing to start the dietary and exercise intervention within 9 months of RPFNA\n\n          -  Willing to complete quality of life questionnaires at multiple visits\n\n          -  Willing to have a medical history and physical at multiple visits\n\n          -  Willing to have an additional RPFNA at two additional visits\n\n          -  Be willing to have blood drawn at multiple visits\n\n          -  Willing to sign and able to understand consent for the RPFNA's and study\n             participation\n\n          -  Reasonable hematopoetic, kidney and liver function consistent with safe participation\n             on this trial.\n\n        Exclusion Criteria:\n\n          -  Having taken medications that seriously affect metabolism such as steroids, dexatrim\n             or other diet drugs within 3 weeks of study registration\n\n          -  Have changed dose or type of hormone supplementation within 3 months\n\n          -  Currently receiving other investigational agents\n\n          -  Have been on a chemoprevention trial within 6 months or taken a Selective Estrogen\n             Receptor Modulator or aromatase inhibitor within last 6 months.\n\n          -  Need for chronic use of aspirin, nonsteroidal anti-inflamatory drug (NSAID) or other\n             anti-inflammatory agents\n\n          -  Taking metformin, or other diabetes medications\n\n          -  Taking statins\n\n          -  Unable to participate in moderate intensity exercise (walking, treadmill, elliptical,\n             water aerobics)\n\n          -  Would be unable to participate, by phone, in weekly phone call sessions\n\n          -  Cells suspicious for malignancy as assessed by cytotechnologist or cytopathologist."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101970", 
            "org_study_id": "STUDY00000703"
        }, 
        "intervention": [
            {
                "arm_group_label": "Weight Loss + Omega-3 FA", 
                "description": "Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)", 
                "intervention_name": "Omega-3 Fatty Acids", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Eicosapentaenoic Acid (EPA)", 
                    "Docosahexaenoic Acid (DHA)"
                ]
            }, 
            {
                "arm_group_label": "Weight Loss + Placebo", 
                "intervention_name": "Placebo Capsule", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Weight Loss + Omega-3 FA", 
                    "Weight Loss + Placebo"
                ], 
                "description": "Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.", 
                "intervention_name": "Diet and Exercise", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast cancer risk", 
            "DHA", 
            "Omega-3 Fatty Acids", 
            "EPA", 
            "Weight Loss"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "contact": {
                "email": "jnydegger@kumc.edu", 
                "last_name": "Jennifer Nydegger", 
                "phone": "913-588-3963"
            }, 
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66205"
                }, 
                "name": "University of Kansas Medical Center, Breast Cancer Prevention Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention", 
        "overall_contact": {
            "email": "bkimler@kumc.edu", 
            "last_name": "Bruce Kimler, PhD", 
            "phone": "(913) 588-4523"
        }, 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Carol J. Fabian, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured as the number of participants that dropout before diet+intervention period is complete", 
            "measure": "Dropout rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101970"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kansas Medical Center Research Institute", 
            "investigator_full_name": "Carol Fabian, MD", 
            "investigator_title": "Professor, Director Breast Cancer Prevention Unit", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Based on eligibility criteria, study procedures and participation of subjects the study design will be measured to see if it will practically work with a larger study population", 
                "measure": "Study design feasibility", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Measure the change in fasting and postprandial blood inflammatory, and risk biomarkers", 
                "measure": "Modulation of breast cancer risk biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 6 Months"
            }, 
            {
                "description": "Measure change in fasting and postprandial blood inflammatory, and risk biomarkers", 
                "measure": "Modulation of breast cancer risk biomarkers in benign breast tissue", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 6 Months"
            }, 
            {
                "description": "Measure the change in fasting and postprandial blood inflammatory, and risk biomarkers", 
                "measure": "Modulation of breast cancer risk biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 12 Months"
            }, 
            {
                "description": "Measure change in fasting and postprandial blood inflammatory, and risk biomarkers", 
                "measure": "Modulation of breast cancer risk biomarkers in benign breast tissue", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 12 Months"
            }, 
            {
                "description": "Measure change in weight in participants during the 6-12 month maintenance phase", 
                "measure": "Weight gain", 
                "safety_issue": "No", 
                "time_frame": "Change from 6 Months to 12 Months"
            }, 
            {
                "description": "Change in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA):arachidonic acid (AA) ratio", 
                "measure": "Change in Gut Microbiome", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to Month 6"
            }
        ], 
        "source": "University of Kansas", 
        "sponsors": {
            "collaborator": {
                "agency": "DSM Nutritional Products, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Carol Fabian, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}